

BioSpectrum Ranking Survey: Rank 14: Concord Biotech

16 September 2016 | Features | By BioSpectrum Bureau

BioSpectrum Ranking Survey: Rank 14: Concord Biotech

Concord Biotech
CMD: Sudhir Vaid
Revenue: Rs 272.9 crore

Gujarat-based pharmaceutical firm Concord Biotech is driven by a strategic focus on biopharmaceuticals APIs. It is said to be India's leading manufacturer of fermentation and semi-synthesis-based biopharmaceutical APIs, focused on niche segments such as immunosuppressant and oncology.

From a single product company in early 2000, Concord today has a product portfolio and near term pipeline of over 30 products across niche therapies such as immunosuppressant, oncology, antifungal and antibacterial.

The company has commercial operations in more than 50 countries with significant revenue contributions from products that are sold in regulated markets such as USA, Europe and Japan.

It also offers contract research and manufacturing services (CRAMs) in the areas of natural products and is working with global biotech companies in the area of CRAMs.

From single manufacturing block in 2000, now Concord has built-up more than 20 dedicated biotech blocks, with total fermentation capacity over 500 cubic metres. Concord is coming up with a new formulation facility in Ahmedabad, and

expects to start operations by end of 2016.

The company has launched several products in the area of oncology, immunosuppressant, anti-fungal and anti-Infectives. On some of these products, the company has got associated with formulation companies on P-IV opportunity.

Concord has also entered into Contract Research & Manufacturing agreements with global biopharmaceutical companies in the area of natural products and semi-synthetic products.

Company has set up a new formulation facility for Oral Solid Dosage (OSD) to cater to global markets and expects to file ANDAs in FY2016-17.

The company feels that getting faster land and environment clearance from the state and Centre for newer biotechnology manufacturing units would definitely help in getting early access to markets.